Haleon Q1 Earnings Call Highlights

1 hour ago 1

Haleon logo

3 inexpensive 'stock'-ing stuffers Wall Street is bullish on

Haleon (NYSE:HLN) reported 2.2% integrated gross growth successful its first-quarter trading update, arsenic absorption pointed to continued unit connected user assurance and a weaker-than-usual acold and flu season. The institution reiterated its full-year outlook, portion highlighting ongoing productivity-driven borderline betterment and plans to summation concern successful definite maturation initiatives.

Q1 maturation held backmost by anemic acold and flu play

Chief Executive Officer Brian McNamara said Haleon “navigated a challenging market” successful the quarter, with user assurance continuing to weaken. He noted that the “continued weakness successful acold and flu” reduced radical integrated maturation by 130 ground points.

→ Pipelines and Automation: 2 Energy Plays Built for Any Oil Price

Chief Financial Officer Dawn Allen said the quarter’s 2.2% integrated gross growth reflected 2.4% from price and a 0.2% diminution successful volume/mix. Allen added that class penetration remained “resilient,” but consumers are becoming “more value-orientated and seeking much convenience.”

Oral wellness led the portfolio; VMS improved

Haleon’s oral wellness concern was again a cardinal driver, delivering 8.3% integrated gross growth, which Allen said was “2x up of the market.” She attributed U.S. show to innovation rollouts including Sensodyne Clinical Repair and parodontax Gum Strengthen & Protect, saying this contributed to “double-digit depletion growth.” In India, she highlighted the INR 20 Sensodyne pack, noting that 70% of units were purchased by caller consumers to the brand.

→ Homebuilder Earnings: D.R. Horton Sticks Out arsenic Pulte & NVR Sales Tank

In vitamins, minerals and supplements (VMS), Haleon posted 1.7% integrated gross growth, with betterment “largely driven by Centrum,” according to Allen. She said Centrum grew mid-single digit successful North America, supported by the motorboat of Centrum Nutrient Replenish targeted astatine GLP-1 users, positive continued spot successful Centrum Silver aided by “activation of biologic aging claims.” In China, she said upgraded regular kits performed well. Caltrate growth, she added, was affected by a pugnacious comparison.

Over-the-counter (OTC) show was mixed, with Allen citing spot successful Panadol, Benefiber, and Tums offset by the anemic acold and flu play and declines successful Smoker’s Health and Nexium. Respiratory declined 3.4% organically, arsenic astir 60% of Haleon’s respiratory portfolio is positioned against the acold and flu category, which fell crossed respective markets successful the quarter.